Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Oral Communications

Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2

ea0090oc9.1 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Identification of adrenocortical masses malignancy and aggressivity through radiomics: a pilot study

Tucci Lorenzo , Vara Giulio , Improta Ilaria , Leo Antonio De , Selva Saverio , Balacchi Caterina , Santini Donatella , Mosconi Cristina , Vicennati Valentina , Pagotto Uberto , Dalmazi Guido Di

Background: Adrenal lipid poor adenoma (LPA) and adrenocortical cancer (ACC) may overlap in computerized tomography (CT). Radiomics recently emerged as new tool for malignant behavior identification.Aim: To assess radiomics utility for identification of ACC and LPA in adrenocortical masses with unenhanced (UE) CT scan attenuationā‰„10 Hounsfield Unit (HU).Methods: We retrospectively enrolled 50 patients, 38 radiologically defin...

ea0090oc9.2 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

FLNA-binding partner Wee1 as a new potential pharmacological target in adrenocortical carcinomas

Esposito Emanuela , Catalano Rosa , Nozza Emma , Barbieri Anna Maria , Maioli Sara , Albrecht Ernst Geginat Jens , Marra Giusy , Treppiedi Donatella , Muro Genesio Di , Mangili Federica , Hantel Costanze , Palmieri Serena , Frigerio Sofia , Ferrante Emanuele , Arosio Maura , Mantovani Giovanna , Peverelli Erika

The cytoskeletal actin-binding protein filamin A (FLNA) is poorly expressed in adrenocortical carcinomas (ACC) compared to adenomas (ACA), and this might contribute to sustain the increased cell proliferation by downregulating IGF1R expression and its downstream signaling. In mouse neural progenitor cells, increased protein expression levels of the CDK1 kinase Wee1 have been found after loss of FLNA. This protein has a leading role in regulating the G2-M checkpoint and functio...

ea0090oc9.3 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Prolonged exposure to target mitotane concentrations is associated with better recurrence-free survival in patients with adrenocortical carcinoma on adjuvant treatment

Puglisi Soraya , Calabrese Anna , Basile Vittoria , Kimpel Otilia , Altieri Barbara , Angelousi Anna , Kaltsas Gregory , Ambroziak Urszula , Appetecchia Marialuisa , Arosio Maura , Berruti Alfredo , Cosentini Deborah , Canu Letizia , Ceccato Filippo , Dalmazi Guido Di , Bouys Lucas , Libe Rossella , Papierska Lucyna , Pittaway James , Kienitz Tina , Quinkler Marcus , Elhassan Yasir , Ronchi Cristina , Saiegh Leonard , Stigliano Antonio , Dusek Tina , Kastelan Darko , Fassnacht Martin , Terzolo Massimo

Background: The management of adjuvant mitotane therapy in patients with adrenocortical carcinoma (ACC) is challenging. Plasma mitotane concentrations>14 mg/l have been associated with efficacy in the treatment of advanced ACC; however, data in the adjuvant setting are mixed. Moreover, there is no consensus on how to assess the optimal exposure to mitotane and all the proposed methods have inherent limitations. We have recently proposed a new method analogous to what is es...

ea0090oc9.4 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma

Altieri Barbara , Kimpel Otilia , Megerle Felix , Detomas Mario , Chifu Irina , Quinkler Marcus , Matthias Kroiss , Fassnacht Martin

Background: Mitotane is regularly used in patients with adrenocortical carcinoma (ACC) adjuvantly, in patients with high risk of recurrence, and in advanced disease. Multiple effects of mitotane result in adrenal insufficiency in virtually all patients. However, it is unclear how frequently the hypothalamic-pituitary-adrenal (HPA) axis is recovering after treatment discontinuation. Here, we aim to investigate the HPA axis after treatment with mitotane.Me...

ea0090oc9.5 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Generation of novel tools for the study and development of targeted therapeutic approaches for pheochromocytoma and paraganglioma

Kemkem Yasmine , Santambrogio Alice , Montibus Bertille , Willis Thea , Kaufman-Cook James , Lodge Emily , Yianni Val , J. Oakey Rebecca , L. Andoniadou Cynthia

Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumours, which arise from neural crest (NC)-derived structures: the adrenal medulla and the paraganglia. Around one third of PPGLs are associated with inherited cancer susceptibility genes, the highest rate among all tumour types. Currently, the only diagnostic criterion for malignant disease is the presence of metastasis and no molecular or histological features have been identified that help predict risk. A...

ea0090oc9.6 | Oral Communications 9: Adrenal and Cardiovascular Endocrinology 2 | ECE2023

Previous use of anabolic androgenic steroids is associated with persistent impaired myocardial microcirulation

Bulut Yeliz , J. Rasmussen Jon , Brandt-Jacobsen Niels , Lassen Martin Lyngby , Hasbak Philip , Kistorp Caroline

Background and Aim: Ongoing anabolic androgenic steroids (AAS) use has been linked with left ventricle dysfunction, while information on the effects years after discontinuation is limited. Furthermore, the underlying mechanism behind the impaired cardiac function is unknown. Early signs of cardiomyopathy, such as microvascular dysfunction with global or regional reduced myocardial perfusion can be measured noninvasively by cardiac positron emission tomography (PET) with Rubidi...